Using new non-contrast MRI sequences to improve diagnosis and grading of prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-center observational effort that performs both conventional multiparametric MRI and novel non-contrast MRI sequences (for example MAGiC, OGSE, CEST, IVIM) on patients with clinical suspicion of prostate cancer. Imaging results from the new sequences will be compared to conventional MRI findings and to surgical or biopsy pathology as the gold standard. The goal is to determine whether adding these sequences improves detection accuracy and tumor grading without using contrast. Eligibility focuses on patients with elevated total PSA and no prior prostate cancer treatment or contraindications to MRI.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with a high clinical suspicion of prostate cancer and elevated tPSA levels;
2. Patients with no prior history of other tumors;
3. Patients with no contraindications to MRI, including claustrophobia, presence of pacemakers, cardiac stents, or metal implants such as screws and plates.

Exclusion Criteria:

1. The patient has a history of malignant tumors and has received corresponding treatment;
2. Prior to the MRI examination, the patient has undergone treatment for prostate cancer, including endocrine therapy, radiotherapy, etc.;
3. Patients who have previously undergone radical prostatectomy for prostate cancer.

Where it's running

• The First Affiliated Hospital of Soochow University
  Suzhou, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Qian Zhang
• Email: zhangqian0194@163.com
• Phone: +86 15137562688

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Epidemiology, diagnosis, and treatment patterns of prostate cancer in Algeria

  This project collects medical and treatment information to see how prostate cancer is diagnosed and managed in Algerian men with confirmed disease.

  Recruiting at 21 sites Société Algérienne de Formation et Recherche en Oncologie · Adrar, Algeria and 23 other locations · NCT07484971

• PROSTest test in men with elevated PSA to aid prostate cancer decisions

  This study tests PROSTest in men with elevated PSA to see if it can accurately detect prostate cancer using biopsy results as the reference.

  Recruiting Wren Laboratories LLC · Branford, Connecticut · NCT07454603

• MRI- and PHI-guided approach to decide when a prostate biopsy is needed

  This trial will test whether using multiparametric MRI together with the Prostate Health Index (PHI) can safely reduce unnecessary prostate biopsies in biopsy-naïve men with suspected prostate cancer and PSA 3–20 ng/mL.

  Recruiting Asan Medical Center · Seoul · NCT07398690

• Digital exercise program with live virtual group sessions for men on hormone therapy during radiotherapy

  This program will test whether a digital exercise program with live virtual group sessions helps men with prostate cancer who are starting or receiving hormone therapy with radiotherapy stick to exercise recommendations and improve health and fatigue.

  Recruiting Royal Marsden NHS Foundation Trust · London · NCT07243834

• Comparing Lutetium-177 and Actinium-225 PSMA-targeted radiation before prostatectomy

  This will test whether giving one of two PSMA-targeted radiation drugs (Lutetium-177 or Actinium-225) before prostate removal works differently in men with high or very high-risk localized prostate cancer.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07054346

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.